“showed a trend”

Iloprost showed a trend toward reduced digital amputation risk, although heterogeneity was high (RR = 0.09; 95% CI: 0.00–5.04; p =.24; I 2 = 88%).

Although not shown to be statistically significant, sites without the pharmacist intervention were analyzed during the same timeframe and showed a trend toward improvement in patient enrollment, from 3.2 to 4.9 patients per month ( p = .24) after the release of the weekly report.

Of note is that the burned group (n = 4) showed a trend toward reduced adipocyte count compared to unburned controls (p = 0.24).

Although Child’s B and C patients showed a trend to higher myostatin levels, these were not significantly different of those observed among Child’s A patients (KW = 2.83; p = 0.24).

They also showed a trend for higher serum levels of a-fetoprotein, which is a diagnostic marker of HCC ( p = 0.24).

The concentrations of NT-proBNP showed a trend to decrease from 988 (25–75% IQR = 745–1126) pmol/mL to 843 (25–75% IQR = 697–985) pmol/mL (Δ% = −14.7%, p = 0.24). 3.3.

While our cohort of ALK-positive NSCLC patients was heterogeneous in terms of their treatment history prior to blood collection, higher ALK autoantibody levels showed a trend toward more favorable overall survival outcomes (P=0.24, Figure 4 ), although there were several early censoring events in this analysis.

At T0, patients who developed n-BSI showed a trend toward an increase of LBP (median, IQR, ng/mL) than those without n-BSI [34470 (27580-47790) vs 25050 (10334-49250), p=0.24] ( Figure 3A ).

The same allele T of IGF1 rs6214 showed a trend of association with longer lens thickness in both STM and NAI cohorts (β±SE=0.049±0.041 mm, p=0.240; and β±SE=0.06±0.03 mm, p=0.027, respectively, Table 4 ).

This showed a trend towards improvement compared to baseline at 12 weeks with a mean (SE) decrease in score of −7 (5), p = 0.24 (ITT, Table 2 ), which was maintained to week 48 and to week 72 (after treatment had stopped), by ITT and PP analysis ( Figure 3 ).

Short‐term (6 weeks) treatment did not significantly alter plaque size between groups, although warfarin showed a trend toward smaller plaques compared with control and dabigatran treatment ( p = .24 and p = .09 for warfarin vs control and DE, respectively; Figure 1B ).

PAM showed a trend for higher success than PAC, in both fully susceptible (ER = 95% vs ER = 91%, p = 0.241) and single-resistant strains (ER = 88% vs ER = 83%, p = 0.383) (Table 2 , Supplementary 6).

Intriguingly, patients of over 60 years showed a trend towards better GHS scores than the younger patients in follow-up care (74.14% vs. 64.72%, p = 0.241).

After 1 year of treatment, patients diagnosed with PsA were less likely to persist with secukinumab than those with AxSpA with an HR of 12.32 (95% CI 1.6–94.9, p = 0.016), obese patients showed a non-significant trend to discontinuation with respect to the non-obese with an HR of 2.54 (95% CI 0.99–6.50, p = 0.051) and women showed a trend toward a better retention rate that men with an HR of 0.29 (95% CI 0.04–2.28, p = 0.241).

Comparing patients with and without shocks also showed a trend towards higher programmed VF zones (≥ 210 BPM) at end of study follow-up in the patients without shocks (79 vs. 89%; P = 0.243, Table 3 ), though not significant.

Although vertical DSM showed a trend toward worse BCVA compared to round DSM (estimate = 0.144 logMAR; P = 0.243), this difference was not statistically significant.

Specifically, the difference in the right PVS number showed a trend-level effect after FDR correction (FDR-adjusted P = 0.245, Cohen's d = 0.479), and the difference in the left DTI-ALPS index also demonstrated a trend-level effect after FDR correction (FDR-adjusted P = 0.074, Cohen's d = 0.513).

Patients who took acetazolamide showed a trend towards better MDI scores than patients on topiramate or without medication ( p = 0.246, supplementary Table 1 in ESM).

Compared to CRT alone, the durvalumab combined with concurrent CRT group showed a trend toward improved PFS (median PFS: 13.8 vs. 9.4 months; HR = 0.85; 95% CI: 0.65–1.12; p = 0.247), without statistical significance [ 56 ].

Regarding the subgroup of patients with a TPS score > 50%, the parameter PET-Skewness also showed a trend in favor of patients with a value below the above-mentioned threshold (HR for disease progression or death, 0.57; 95% CI, 0.22 to 1.48; p = 0.247; Figure 5 A).

The risk of CME development showed a trend toward lower CME rates in the FLACS group than the CPCS group, whether defined as appearance of cystoid changes near fovea on OCT imaging ( p =0.247) or using PREMED study criteria ( p =0.586).

Results During the bracing phase, the IOFS showed a trend towards lower scores when compared to the casting phase for both cohorts ( p = 0.247 and p = 0.434, respectively).

Patients whose tumors retained membrane claudin 1 expression in more than 10% of the tumor cells showed a trend towards increased survival (Kaplan-Meier analysis, p=0.25).

Women showed a trend towards better survival than men (25.7% vs 19.2%, P = 0.25), and the trend was even more pronounced for patients with COPD.

At 4 months post-therapy, animals in the S-CDCs group showed a trend towards higher LVEF than the swine belonging to CON group (35 ± 10% vs. 29 ± 10%, p = 0.25) ( Figure 3 A).